Alaunos Therapeutics Reports Executive Changes and Compensation Updates
Ticker: TCRT · Form: 8-K · Filed: Feb 22, 2024 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 8-K |
| Filed Date | Feb 22, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $15,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Alaunos Therapeutics just dropped an 8-K about executive changes and compensation, so keep an eye on leadership shifts!**
AI Summary
Alaunos Therapeutics, Inc. filed an 8-K on February 22, 2024, reporting events from February 15, 2024. The filing pertains to the departure or election of directors and certain officers, as well as compensatory arrangements for officers. This indicates potential changes in the company's leadership or executive compensation structure.
Why It Matters
Changes in executive leadership and compensation can signal strategic shifts or financial adjustments within a company, impacting its future direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in executive leadership can introduce uncertainty regarding future company strategy and performance, warranting a medium risk assessment.
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — Registrant
- February 15, 2024 (date) — Date of earliest event reported
- February 22, 2024 (date) — Filing date
- 001-33038 (other) — Commission File Number
- Delaware (other) — State of incorporation
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 15, 2024.
What is the primary subject matter of this 8-K filing?
The primary subject matter of this 8-K filing is the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers'.
When was this 8-K filed with the SEC?
This 8-K was filed with the SEC on February 22, 2024.
What is the full legal name of the registrant company?
The full legal name of the registrant company is Alaunos Therapeutics, Inc.
What is the Commission File Number for Alaunos Therapeutics, Inc.?
The Commission File Number for Alaunos Therapeutics, Inc. is 001-33038.
Filing Stats: 900 words · 4 min read · ~3 pages · Grade level 10.9 · Accepted 2024-02-22 16:44:55
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share TCRT The Nasdaq Stock Mar
- $15,000 — des for compensation at a fixed rate of $15,000 per month and reimbursement by the Comp
Filing Documents
- d929353d8k.htm (8-K) — 25KB
- 0001193125-24-042903.txt ( ) — 145KB
- tcrt-20240215.xsd (EX-101.SCH) — 3KB
- tcrt-20240215_lab.xml (EX-101.LAB) — 18KB
- tcrt-20240215_pre.xml (EX-101.PRE) — 11KB
- d929353d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alaunos Therapeutics, Inc. Date: February 22, 2024 By: /s/ Dale Curtis Hogue, Jr. Name: Dale Curtis Hogue, Jr. Title: Interim Chief Executive Officer